321 related articles for article (PubMed ID: 20956469)
21. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
Kamen BA; Smith AK
Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
[TBL] [Abstract][Full Text] [Related]
22. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
[TBL] [Abstract][Full Text] [Related]
23. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
24. Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
Fischer CR; Groehn V; Reber J; Schibli R; Ametamey SM; Müller C
Mol Imaging Biol; 2013 Dec; 15(6):649-54. PubMed ID: 23760583
[TBL] [Abstract][Full Text] [Related]
25. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Müller C; Brühlmeier M; Schubiger PA; Schibli R
J Nucl Med; 2006 Dec; 47(12):2057-64. PubMed ID: 17138750
[TBL] [Abstract][Full Text] [Related]
26. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics.
Litau S; Niedermoser S; Vogler N; Roscher M; Schirrmacher R; Fricker G; Wängler B; Wängler C
Bioconjug Chem; 2015 Dec; 26(12):2350-9. PubMed ID: 26420336
[TBL] [Abstract][Full Text] [Related]
27. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
Müller C; Bunka M; Reber J; Fischer C; Zhernosekov K; Türler A; Schibli R
J Nucl Med; 2013 Dec; 54(12):2168-74. PubMed ID: 24198390
[TBL] [Abstract][Full Text] [Related]
28. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys.
Müller C; Schibli R; Forrer F; Krenning EP; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):603-8. PubMed ID: 17707799
[TBL] [Abstract][Full Text] [Related]
30. 18 F-click labeling and preclinical evaluation of a new 18 F-folate for PET imaging.
Schieferstein H; Betzel T; Fischer CR; Ross TL
EJNMMI Res; 2013 Sep; 3(1):68. PubMed ID: 24041035
[TBL] [Abstract][Full Text] [Related]
31. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
32. Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.
Fani M; Wang X; Nicolas G; Medina C; Raynal I; Port M; Maecke HR
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):108-19. PubMed ID: 20799032
[TBL] [Abstract][Full Text] [Related]
33. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
34. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy.
Reber J; Haller S; Leamon CP; Müller C
Mol Cancer Ther; 2013 Nov; 12(11):2436-45. PubMed ID: 24030631
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
36. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
[TBL] [Abstract][Full Text] [Related]
37. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.
Müller C; Forrer F; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Feb; 49(2):310-7. PubMed ID: 18199624
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
39. (18)F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ1 Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent.
Xie F; Bergmann R; Kniess T; Deuther-Conrad W; Mamat C; Neuber C; Liu B; Steinbach J; Brust P; Pietzsch J; Jia H
J Med Chem; 2015 Jul; 58(14):5395-407. PubMed ID: 26090686
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
